-
Mashup Score: 0Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C - 3 month(s) ago
AbstractBackground. National Cancer Institute-Children’s Oncology Group Pediatric Molecular Analysis for Therapy Choice assigns patients aged 1-21 years with re
Source: academic.oup.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
Further refinement of biomarkers for tazemetostat activity in malignant pleural mesothelioma beyond BAP1 inactivation could help identify a subset of tumours that are most likely to derive prolonged benefit or shrinkage from this therapy.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Online first: EZH2 inhibitor #tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural #mesothelioma: a multicentre, open-label, phase 2 study https://t.co/YrHWGXhQwK
-
-
Mashup Score: 2Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma - Full Text View - ClinicalTrials.gov - 3 year(s) ago
Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma – Full Text View.
Source: www.clinicaltrials.govCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#TrialTuesday: Learn more about this phase 3 #ClinicalTrial led at SKCC by @basumallickmd, which will help determine the recommend dose of #tazemetostat + #doxorubicin for patients with advanced epithelioid #sarcoma: https://t.co/GqdfnFMai3 @EpizymeRx #SarcomaAwarenessMonth https://t.co/Sg1Yxu0NJt
-
-
Mashup Score: 5EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer - 3 year(s) ago
Ellis and colleagues show that combination of EZH2 inhibition and anti-PD-1 can increase antitumor immune responses in typically ‘immune cold’ prostate cancer, by increasing EZH2-regulated dsRNA–STING–ISG response signaling.
Source: Nature CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
Excited to share-our recent @NatureCancer paper has led to initiation of a neoadj trial in #ProstateCancer patients w #Tazemetostat from @EpizymeRx @CSCancerCare @EdwinPosadasMD @TimDaskivich @soulehoward1 @PCF_Science https://t.co/OcIrVMo167
-
-
Mashup Score: 1Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study - 4 year(s) ago
Tazemetostat was well tolerated and showed clinical activity in this cohort of patients with advanced epithelioid sarcoma characterised by loss of INI1/SMARCB1. Tazemetostat has the potential to improve outcomes in patients with advanced epithelioid sarcoma. A phase 1b/3 trial of tazemetostat plus doxorubicin in the front-line setting is currently underway (NCT04204941).
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In our Nov issue: #Tazemetostat in advanced epithelioid #sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study https://t.co/4VkGhpuO4c https://t.co/2vC0AQ49e4
-
-
Mashup Score: 0Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial - 4 year(s) ago
Tazemetostat monotherapy showed clinically meaningful, durable responses and was generally well tolerated in heavily pretreated patients with relapsed or refractory follicular lymphoma. Tazemetostat is a novel treatment for patients with follicular lymphoma.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Also in the Nov issue: #Tazemetostat for patients with relapsed or refractory follicular #lymphoma: an open-label, single-arm, multicentre, phase 2 trial https://t.co/GbFajLUwxc #lymsm https://t.co/AdFGyk5ISW
-
-
Mashup Score: 0
In our exclusive interview, Dr. Leonard discusses the FDA approval of tazemetostat in patients with relapsed/refractory follicular lymphoma whose tumors are EZH2 positive, as well as those with relapsed/refractory follicular lymphoma who have no other available satisfactory treatment options, and the benefits of providing another agent for this subset of patients.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ICYMI: Dr. Leonard discusses the FDA approval of #tazemetostat in patients with relapsed/refractory follicular lymphoma whose tumors are #EZH2 positive @WeillCornell @JohnPLeonardMD https://t.co/L77wPhPZUp https://t.co/LfCT3SOc4v
-
-
Mashup Score: 0
In our exclusive interview, Dr. Leonard discusses the FDA approval of tazemetostat in patients with relapsed/refractory follicular lymphoma whose tumors are EZH2 positive, as well as those with relapsed/refractory follicular lymphoma who have no other available satisfactory treatment options, and the benefits of providing another agent for this subset of patients.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ICYMI: Dr. Leonard discusses the FDA approval of #tazemetostat in patients with relapsed/refractory follicular lymphoma whose tumors are #EZH2 positive @WeillCornell @JohnPLeonardMD https://t.co/L77wPhPZUp https://t.co/XPcZkz7ZxM
-
-
Mashup Score: 5Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study - 4 year(s) ago
Tazemetostat was well tolerated and showed clinical activity in this cohort of patients with advanced epithelioid sarcoma characterised by loss of INI1/SMARCB1. Tazemetostat has the potential to improve outcomes in patients with advanced epithelioid sarcoma. A phase 1b/3 trial of tazemetostat plus doxorubicin in the front-line setting is currently underway (NCT04204941).
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Online first: #Tazemetostat in advanced epithelioid #sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study https://t.co/4VkGhpuO4c
-
-
Mashup Score: 3Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial - 4 year(s) ago
Tazemetostat monotherapy showed clinically meaningful, durable responses and was generally well tolerated in heavily pretreated patients with relapsed or refractory follicular lymphoma. Tazemetostat is a novel treatment for patients with follicular lymphoma.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Also new online: #Tazemetostat for patients with relapsed or refractory follicular #lymphoma: an open-label, single-arm, multicentre, phase 2 trial https://t.co/GbFajLCVFE #lymsm
-
Published in @JNCI_Now: Results from the first Phase 2 trial of #Tazemetostat in pediatric cancer patients with tumors harboring SMARCB1/SMARCA4 or EZH2 alterations treated on the NCI-COG Pediatric MATCH Trial. Read more here: https://t.co/PL4TvJbUQj https://t.co/yqZJAcxPVI